We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer.
- Authors
Galsky, Matthew D; Eisenberger, Mario; Moore-Cooper, Sandra; Kelly, W Kevin; Slovin, Susan F; DeLaCruz, Anthony; Lee, Yih; Webb, Iain J; Scher, Howard I
- Abstract
MLN2704 is an immunoconjugate designed to deliver the maytansinoid antimicrotubule agent drug maytansinoid-1 directly to prostate-specific membrane antigen (PSMA)-expressing cells via the PSMA-targeted monoclonal antibody MLN591. This novel immunoconjugate has shown cytotoxic anti-prostate cancer activity. This study investigated the safety profile, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MLN2704.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Vol 26, Issue 13, p2147
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2007.15.0532